A new drug for pancreatic cancer, Daraxonrasib, has doubled the median survival time of patients in clinical trials and is now recommended for EU approval, which is considered a significant advancement in the treatment of this previously hard-to-treat cancer. #Bauchspeicheldrüsenkrebs #Krebsforschung #Daraxonrasib (translated)










